Skip to main
ACHV

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences is expected to experience significant growth in the near future, driven by the potential approval and launch of its smoking cessation drug, cytisinicline, in the United States in 2027. The company has completed a successful end-of-Phase 2 meeting with the FDA and has a well-defined regulatory path toward approval. Additionally, the company is also working on a potential treatment for vaping cessation, with a high probability of success and reduced risk due to the potential approval of cytisinicline. The upside potential of the stock at its current levels is favorable, with a 60% chance of success and potential partnerships in the future. However, potential risks such as commercial execution, clinical trials, regulatory approvals, and financing still remain a concern.

Bears say

Achieve Life Sciences is facing uncertainty and potential challenges in their FDA review process due to their prior reliance on a third-party manufacturer, which they have since transitioned away from. While today's announcement of no new clinical deficiencies is a positive update, the CRL still affects their timeline for resubmission. Additionally, their reliance on a single product and lack of diversity in their operations poses potential risks for the company's future success.

ACHV has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Strong Buy based on their latest research and market trends.

According to 3 analysts, ACHV has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.